Health Catalyst (HCAT) Financials

Health Catalyst logo
$1.29 -0.08 (-5.84%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$1.29 0.00 (0.00%)
As of 11/18/2026 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Health Catalyst

Annual Income Statements for Health Catalyst

This table shows Health Catalyst's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-114 -241 -115 -153 -137 -118 -70 -178
Consolidated Net Income / (Loss)
-62 -60 -115 -153 -137 -118 -70 -178
Net Income / (Loss) Continuing Operations
-62 -60 -115 -153 -137 -118 -70 -178
Total Pre-Tax Income
-62 -60 -116 -160 -142 -118 -69 -177
Total Operating Income
-60 -55 -96 -144 -140 -127 -70 -161
Total Gross Profit
53 80 91 118 133 132 141 152
Total Revenue
113 155 189 242 276 296 307 311
Operating Revenue
113 155 189 242 276 296 307 311
Total Cost of Revenue
60 75 98 124 143 164 166 159
Operating Cost of Revenue
60 75 98 124 143 164 166 159
Total Operating Expenses
113 134 187 261 273 259 211 313
Selling, General & Admin Expense
23 32 59 86 62 77 57 50
Marketing Expense
44 47 55 75 88 67 54 52
Research & Development Expense
39 46 54 63 76 73 58 50
Depreciation Expense
7.41 9.21 19 38 48 42 41 51
Impairment Charge
- - - - - 0.00 0.00 110
Total Other Income / (Expense), net
-2.02 -5.09 -20 -16 -1.68 9.11 0.64 -16
Interest & Investment Income
- - - - -1.68 9.11 0.64 -16
Income Tax Expense
-0.14 0.14 -1.19 -6.90 -4.28 0.36 0.33 0.72
Basic Earnings per Share
($23.76) ($12.86) ($2.91) ($3.23) ($2.56) ($2.09) ($1.15) ($2.55)
Weighted Average Basic Shares Outstanding
4.80M 18.74M 39.54M 47.49M 53.72M 56.42M 60.18M 69.90M
Diluted Earnings per Share
($23.76) ($12.86) ($2.91) ($3.23) ($2.63) ($2.09) ($1.15) ($2.55)
Weighted Average Diluted Shares Outstanding
4.80M 18.74M 39.54M 47.49M 54.08M 56.42M 60.18M 69.90M
Weighted Average Basic & Diluted Shares Outstanding
4.80M 18.74M 39.54M 53.35M 55.81M 58.56M 70.21M 73.59M

Quarterly Income Statements for Health Catalyst

This table shows Health Catalyst's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-21 -14 -15 -21 -24 -41 -22 -91 -111 -41 40
Consolidated Net Income / (Loss)
-21 -14 -15 -21 -24 -41 -22 -91 -111 -41 40
Net Income / (Loss) Continuing Operations
-21 -14 -15 -21 -24 -41 -22 -91 -111 -41 40
Total Pre-Tax Income
-20 -13 -15 -20 -24 -41 -22 -91 -111 -40 40
Total Operating Income
-23 -16 -14 -18 -20 -37 -18 -86 -106 -36 50
Total Gross Profit
36 36 34 35 36 38 38 39 35 35 24
Total Revenue
75 76 76 80 79 81 76 75 71 70 56
Operating Revenue
75 76 76 80 79 81 76 75 71 70 56
Total Cost of Revenue
39 40 42 45 43 42 39 35 35 36 32
Operating Cost of Revenue
39 40 42 45 43 42 39 35 35 36 32
Total Operating Expenses
59 52 48 52 56 75 55 125 142 71 40
Selling, General & Admin Expense
15 14 12 16 14 8.28 16 11 14 12 12
Marketing Expense
19 13 11 11 15 13 14 10 11 10 8.56
Research & Development Expense
15 14 14 15 15 12 12 9.91 9.78 11 9.50
Depreciation Expense
11 11 9.98 10 12 13 13 13 12 11 9.73
Impairment Charge
- 0.00 0.00 - 0.00 29 0.00 - 96 27 0.00
Total Other Income / (Expense), net
2.34 2.36 -1.51 -2.55 -3.36 -3.80 -4.68 -4.57 -4.14 -3.74 56
Interest Expense
- - - - - - 0.00 - - - 9.49
Interest & Investment Income
2.34 2.36 -1.51 -2.55 -3.36 -3.80 -4.68 -4.57 -4.14 -3.74 -0.54
Other Income / (Expense), net
- - - - - - 0.00 - - - 66
Income Tax Expense
0.11 0.07 -0.48 0.63 0.22 0.08 0.04 0.38 0.41 0.32 -0.39
Basic Earnings per Share
($0.35) ($0.23) ($0.24) ($0.33) ($0.35) ($0.59) ($0.32) ($1.29) ($1.53) ($0.55) $0.54
Weighted Average Basic Shares Outstanding
58.59M 59.30M 60.44M 60.18M 68.55M 69.63M 70.38M 69.90M 72.59M 73.96M 75.39M
Diluted Earnings per Share
($0.35) ($0.23) ($0.24) ($0.33) ($0.35) ($0.59) ($0.32) ($1.29) ($1.53) ($0.55) $0.53
Weighted Average Diluted Shares Outstanding
58.59M 59.30M 60.44M 60.18M 68.55M 69.63M 70.38M 69.90M 72.59M 73.96M 75.93M
Weighted Average Basic & Diluted Shares Outstanding
59.03M 60.47M 60.85M 70.21M 69.60M 70.37M 70.73M 73.59M 73.89M 75.26M 76.16M

Annual Cash Flow Statements for Health Catalyst

This table details how cash moves in and out of Health Catalyst's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
5.45 -10 74 101 -77 -10 143 -199
Net Cash From Operating Activities
-40 -32 -26 -23 -35 -33 15 0.73
Net Cash From Continuing Operating Activities
-40 -32 -26 -23 -35 -33 15 0.73
Net Income / (Loss) Continuing Operations
-62 -60 -115 -153 -137 -118 -70 -178
Consolidated Net Income / (Loss)
-62 -60 -115 -153 -137 -118 -70 -178
Depreciation Expense
7.41 9.21 19 38 48 42 41 51
Amortization Expense
0.39 0.47 9.40 13 -0.74 -8.21 -1.50 2.16
Non-Cash Adjustments To Reconcile Net Income
7.50 23 52 62 78 65 46 149
Changes in Operating Assets and Liabilities, net
6.39 -4.74 9.10 17 -23 -14 -2.08 -23
Net Cash From Investing Activities
21 -210 -83 -140 -39 20 -23 36
Net Cash From Continuing Investing Activities
21 -210 -83 -140 -39 20 -23 36
Purchase of Property, Plant & Equipment
-2.08 -2.02 -7.78 -10 -2.17 -1.24 -1.62 -0.97
Acquisitions
-0.23 -1.94 -103 -48 -30 -13 -81 -42
Purchase of Investments
-14 -256 -190 -261 -309 -291 -168 -65
Sale of Property, Plant & Equipment
0.03 0.06 0.01 0.02 0.03 0.03 0.01 0.04
Sale and/or Maturity of Investments
38 51 219 187 315 337 242 164
Other Investing Activities, net
-0.20 -0.38 -1.44 -6.64 -13 -12 -14 -20
Net Cash From Financing Activities
24 231 183 264 -2.61 2.73 152 -236
Net Cash From Continuing Financing Activities
24 231 183 264 -2.61 2.73 152 -236
Repayment of Debt
0.00 -22 -57 - 0.00 0.00 -3.11 -232
Repurchase of Common Equity
-8.71 -4.61 0.00 0.00 -8.39 -1.81 0.00 -5.00
Issuance of Debt
9.95 47 222 - 0.00 0.00 152 0.00
Issuance of Common Equity
0.00 198 4.27 250 3.15 3.59 2.41 1.51
Other Financing Activities, net
-11 0.94 13 14 2.63 0.95 0.17 0.00
Effect of Exchange Rate Changes
- 0.01 0.03 -0.01 -0.01 0.02 -0.03 0.03
Cash Interest Paid
3.94 5.56 4.98 6.36 5.75 5.75 10 22

Quarterly Cash Flow Statements for Health Catalyst

This table details how cash moves in and out of Health Catalyst's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
95 0.53 126 -79 92 -291 -10 11 9.05 0.73 -6.84
Net Cash From Operating Activities
10 1.61 6.21 -3.53 0.28 -9.00 -0.46 9.91 19 0.28 -1.88
Net Cash From Continuing Operating Activities
10 1.61 6.21 -3.53 0.28 -9.00 -0.46 9.91 19 0.28 -1.88
Net Income / (Loss) Continuing Operations
-21 -14 -15 -21 -24 -41 -22 -91 -111 -41 40
Consolidated Net Income / (Loss)
-21 -14 -15 -21 -24 -41 -22 -91 -111 -41 40
Depreciation Expense
11 11 9.98 10 12 13 13 13 12 11 9.73
Amortization Expense
-1.59 -0.80 0.57 0.32 0.29 0.86 0.47 0.53 0.41 0.25 -0.02
Non-Cash Adjustments To Reconcile Net Income
16 11 10 9.29 9.09 38 15 86 100 31 -52
Changes in Operating Assets and Liabilities, net
5.69 -5.38 0.33 -2.73 2.32 -20 -6.31 1.17 17 -1.21 -0.32
Net Cash From Investing Activities
84 -1.78 7.65 -113 97 -52 -9.35 1.01 -9.41 0.90 158
Net Cash From Continuing Investing Activities
84 -1.78 7.65 -113 97 -52 -9.35 1.01 -9.41 0.90 158
Purchase of Property, Plant & Equipment
-0.21 -0.29 -0.71 -0.41 -0.67 0.23 -0.26 -0.27 -0.34 -0.35 -0.16
Acquisitions
-0.08 -19 -36 -25 -41 -0.29 -0.33 -0.18 -0.55 -0.31 -0.05
Purchase of Investments
-50 - - -118 0.00 -47 -10 -7.91 -25 -19 -0.00
Sale of Property, Plant & Equipment
0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.00 0.01 0.01
Sale and/or Maturity of Investments
137 21 48 36 143 - 6.24 15 21 25 18
Other Investing Activities, net
-2.53 -3.76 -3.57 -4.42 -4.66 -5.43 -4.55 -5.14 -4.60 -4.81 -4.17
Net Cash From Financing Activities
0.86 0.70 112 38 -4.71 -230 -0.54 -0.43 -0.00 -0.45 -163
Net Cash From Continuing Financing Activities
0.86 0.70 112 38 -4.71 -230 -0.54 -0.43 -0.00 -0.45 -163
Repayment of Debt
0.00 - - 0.54 -0.41 -230 -1.07 -0.41 -0.41 -0.41 -163
Issuance of Common Equity
0.84 0.59 0.63 0.35 0.70 0.31 0.53 -0.03 0.40 -0.04 0.27
Effect of Exchange Rate Changes
-0.02 -0.00 0.08 -0.10 -0.01 0.07 -0.05 0.02 -0.05 -0.00 0.02

Annual Balance Sheets for Health Catalyst

This table presents Health Catalyst's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
111 302 578 832 752 702 859 503
Total Current Assets
67 264 330 508 428 393 466 169
Cash & Equivalents
28 18 92 193 116 106 250 51
Short-Term Investments
4.76 210 179 252 247 211 142 45
Accounts Receivable
28 28 48 49 48 60 57 59
Prepaid Expenses
5.32 8.39 11 15 16 15 16 14
Plant, Property, & Equipment, net
4.68 4.30 13 23 26 26 29 34
Total Noncurrent Assets
39 34 235 300 299 283 364 299
Goodwill
3.69 3.69 108 170 186 191 260 209
Intangible Assets
28 26 99 105 92 73 86 78
Other Noncurrent Operating Assets
7.44 4.60 28 26 20 19 18 13
Total Liabilities & Shareholders' Equity
111 302 578 832 752 702 859 503
Total Liabilities
76 102 302 310 327 335 494 257
Total Current Liabilities
42 48 88 93 83 89 326 90
Short-Term Debt
3.46 0.00 14 4.58 - 0.00 231 1.63
Accounts Payable
1.81 3.62 5.33 4.69 4.42 6.64 11 9.36
Accrued Expenses
9.20 8.94 17 24 20 23 26 19
Current Deferred Revenue
25 31 47 57 55 56 53 56
Other Current Liabilities
2.58 5.00 4.62 3.43 3.43 3.36 3.61 3.78
Total Noncurrent Liabilities
34 53 214 217 245 246 168 167
Long-Term Debt
19 48 169 181 227 228 151 152
Noncurrent Deferred Revenue
7.28 1.46 1.88 0.93 0.11 0.08 0.25 0.41
Other Noncurrent Operating Liabilities
8.00 1.98 43 35 18 18 16 15
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-375 201 276 522 425 367 365 246
Total Preferred & Common Equity
-375 201 276 522 425 367 365 246
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-375 201 276 522 425 367 365 246
Common Stock
0.01 811 1,002 1,401 1,425 1,484 1,553 1,609
Retained Earnings
-375 -611 -726 -879 -999 -1,117 -1,187 -1,365
Accumulated Other Comprehensive Income / (Loss)
-0.00 0.07 0.06 -0.07 -0.65 0.03 -0.84 1.59

Quarterly Balance Sheets for Health Catalyst

This table presents Health Catalyst's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
723 713 695 692 813 892 616 587 412 359 237
Total Current Assets
411 408 397 376 457 423 181 165 182 248 133
Cash & Equivalents
116 95 201 202 328 342 51 40 60 61 54
Short-Term Investments
228 253 126 106 59 0.00 47 51 49 43 25
Accounts Receivable
52 46 54 55 52 64 68 60 59 42 41
Prepaid Expenses
15 15 15 13 19 17 15 14 14 12 13
Plant, Property, & Equipment, net
26 26 25 26 28 32 33 33 35 33 34
Total Noncurrent Assets
286 278 273 290 328 437 402 389 195 77 70
Goodwill
186 186 191 206 234 313 286 286 113 11 11
Intangible Assets
79 72 66 67 76 106 98 90 69 56 50
Other Noncurrent Operating Assets
21 20 16 17 17 17 18 14 12 9.52 8.82
Total Liabilities & Shareholders' Equity
723 713 695 692 813 892 616 587 412 359 237
Total Liabilities
333 331 338 335 458 515 269 255 274 258 92
Total Current Liabilities
87 84 92 318 324 340 99 88 108 92 78
Short-Term Debt
- - 3.35 0.89 230 232 1.63 1.63 1.63 1.63 0.00
Accounts Payable
7.97 6.33 5.70 11 14 8.95 8.94 4.94 12 8.34 6.53
Accrued Expenses
16 21 20 18 24 24 17 19 21 24 26
Current Deferred Revenue
60 53 64 56 52 71 67 59 70 43 42
Other Current Liabilities
3.47 3.40 - 232 3.33 3.76 3.88 3.86 3.73 3.70 3.66
Total Noncurrent Liabilities
246 246 246 17 134 175 170 167 166 166 14
Long-Term Debt
227 228 228 0.00 115 151 151 152 152 152 0.00
Noncurrent Deferred Revenue
0.09 0.31 0.08 0.05 0.26 0.41 0.33 0.39 0.23 0.43 1.03
Other Noncurrent Operating Liabilities
19 18 0.09 17 19 23 18 15 14 14 13
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
390 382 357 357 355 377 348 332 138 101 146
Total Preferred & Common Equity
390 382 357 357 355 377 348 332 138 101 146
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
390 382 357 357 355 377 348 332 138 101 146
Common Stock
1,455 1,469 1,495 1,508 1,521 1,587 1,597 1,604 1,613 1,616 1,620
Retained Earnings
-1,065 -1,087 -1,138 -1,151 -1,166 -1,210 -1,251 -1,274 -1,476 -1,516 -1,476
Accumulated Other Comprehensive Income / (Loss)
-0.20 -0.17 -0.12 -0.16 -0.11 0.14 2.23 1.51 1.01 1.03 1.02

Annual Metrics And Ratios for Health Catalyst

This table displays calculated financial ratios and metrics derived from Health Catalyst's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 36,565,033.00 42,498,469.00 52,055,293.00 - - - 70,730,884.00
DEI Adjusted Shares Outstanding
0.00 36,565,033.00 42,498,469.00 52,055,293.00 - - - 70,730,884.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -6.59 -2.71 -2.94 - - - -2.52
Growth Metrics
- - - - - - - -
Revenue Growth
0.00% 37.63% 21.88% 28.11% 14.18% 7.13% 3.60% 1.48%
EBITDA Growth
0.00% 13.59% -50.48% -36.73% 0.57% -0.47% 67.83% -262.14%
EBIT Growth
0.00% 8.70% -75.20% -49.44% 2.54% 9.36% 44.99% -130.43%
NOPAT Growth
0.00% 8.70% -75.20% -49.44% 2.54% 9.36% 44.99% -130.43%
Net Income Growth
0.00% 3.05% -91.39% -33.21% 10.32% 14.01% 41.17% -156.07%
EPS Growth
0.00% 45.88% 77.37% -11.00% 18.58% 20.53% 44.98% -121.74%
Operating Cash Flow Growth
0.00% 20.13% 18.75% 11.57% -52.53% 6.21% 144.01% -94.98%
Free Cash Flow Firm Growth
0.00% 0.00% -536.71% 25.25% 29.29% 36.79% -63.06% 52.57%
Invested Capital Growth
0.00% -7.17% 741.17% 39.22% 9.67% -3.76% 28.26% -14.70%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 4.96% 1.64% 2.04% 1.50% -1.56%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% -2.60% 4.03% 1.41% 37.72% -154.92%
EBIT Q/Q Growth
0.00% 0.00% 0.00% -4.24% 5.42% 3.03% 17.96% -74.32%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% -4.24% 5.42% 3.03% 17.96% -74.32%
Net Income Q/Q Growth
0.00% 0.00% 0.00% -4.06% 8.77% 4.43% 12.18% -65.37%
EPS Q/Q Growth
0.00% 0.00% 0.00% 2.71% 11.15% 5.00% 14.18% -60.38%
Operating Cash Flow Q/Q Growth
0.00% -0.23% 25.44% -32.21% -16.70% -14.62% 1,624.50% 105.75%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 57.88% -14.75% -15.61% 58.48%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 171.82% 0.72% 5.67% 13.67% -22.93%
Profitability Metrics
- - - - - - - -
Gross Margin
46.83% 51.37% 48.06% 48.60% 48.21% 44.55% 45.92% 48.75%
EBITDA Margin
-46.45% -29.16% -36.01% -38.43% -33.47% -31.39% -9.74% -34.77%
Operating Margin
-53.38% -35.41% -50.90% -59.38% -50.68% -42.88% -22.77% -51.70%
EBIT Margin
-53.38% -35.41% -50.90% -59.38% -50.68% -42.88% -22.77% -51.70%
Profit (Net Income) Margin
-55.06% -38.79% -60.91% -63.33% -49.74% -39.92% -22.67% -57.20%
Tax Burden Percent
99.78% 100.24% 98.97% 95.69% 96.98% 100.30% 100.48% 100.40%
Interest Burden Percent
103.37% 109.28% 120.90% 111.46% 101.20% 92.82% 99.09% 110.20%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-174.13% -164.88% -63.76% -44.56% -35.59% -31.43% -15.44% -34.18%
ROIC Less NNEP Spread (ROIC-NNEP)
8.28% -141.95% -27.82% -14.21% -15.72% -5.56% 26.11% -307.27%
Return on Net Nonoperating Assets (RNNOA)
-2.58% 113.89% 15.51% 6.17% 6.58% 1.59% -3.54% -24.08%
Return on Equity (ROE)
-176.71% -50.99% -48.25% -38.39% -29.02% -29.84% -18.99% -58.26%
Cash Return on Invested Capital (CROIC)
0.00% -157.45% -221.26% -77.35% -44.82% -27.60% -40.20% -18.31%
Operating Return on Assets (OROA)
-54.15% -26.55% -21.84% -20.38% -17.67% -17.45% -8.95% -23.63%
Return on Assets (ROA)
-55.85% -29.08% -26.14% -21.73% -17.34% -16.25% -8.91% -26.14%
Return on Common Equity (ROCE)
1,887.98% 37.67% -48.25% -38.39% -29.02% -29.84% -18.99% -58.26%
Return on Equity Simple (ROE_SIMPLE)
16.54% -29.95% -41.66% -29.35% -32.33% -32.20% -19.03% 0.00%
Net Operating Profit after Tax (NOPAT)
-42 -38 -67 -101 -98 -89 -49 -113
NOPAT Margin
-37.37% -24.79% -35.63% -41.56% -35.48% -30.02% -15.94% -36.19%
Net Nonoperating Expense Percent (NNEP)
-182.41% -22.94% -35.93% -30.36% -19.88% -25.87% -41.55% 273.09%
Return On Investment Capital (ROIC_SIMPLE)
- - - - -15.04% -14.93% -6.54% -28.22%
Cost of Revenue to Revenue
53.17% 48.63% 51.94% 51.40% 51.79% 55.45% 54.08% 51.25%
SG&A Expenses to Revenue
20.16% 20.47% 31.37% 35.52% 22.34% 25.87% 18.53% 15.93%
R&D to Revenue
34.28% 29.85% 28.34% 25.93% 27.40% 24.54% 18.90% 16.00%
Operating Expenses to Revenue
100.22% 86.78% 98.97% 107.98% 98.90% 87.43% 68.69% 100.45%
Earnings before Interest and Taxes (EBIT)
-60 -55 -96 -144 -140 -127 -70 -161
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-52 -45 -68 -93 -92 -93 -30 -108
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
0.00 6.32 6.70 3.95 1.37 1.45 1.18 0.69
Price to Tangible Book Value (P/TBV)
0.00 7.40 26.67 8.34 3.96 5.18 22.18 0.00
Price to Revenue (P/Rev)
1.62 8.19 9.80 8.53 2.11 1.80 1.40 0.54
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
24.05 48.55 9.34 6.86 1.55 1.60 1.18 0.75
Enterprise Value to Revenue (EV/Rev)
5.16 7.03 9.33 7.45 1.61 1.50 1.37 0.73
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 28.89 309.94
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - -
Debt to Equity
0.64 0.24 0.66 0.36 0.53 0.62 1.05 0.62
Long-Term Debt to Equity
0.54 0.24 0.61 0.35 0.53 0.62 0.41 0.62
Financial Leverage
-0.31 -0.80 -0.56 -0.43 -0.42 -0.29 -0.14 0.08
Leverage Ratio
3.16 1.75 1.85 1.77 1.67 1.84 2.13 2.23
Compound Leverage Factor
3.27 1.92 2.23 1.97 1.69 1.70 2.11 2.46
Debt to Total Capital
38.84% 19.37% 39.92% 26.22% 34.77% 38.33% 51.15% 38.41%
Short-Term Debt to Total Capital
6.03% 0.00% 3.14% 0.65% 0.00% 0.00% 30.92% 0.41%
Long-Term Debt to Total Capital
32.81% 19.37% 36.78% 25.57% 34.77% 38.33% 20.22% 38.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
714.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-653.48% 80.63% 60.08% 73.78% 65.23% 61.67% 48.85% 61.59%
Debt to EBITDA
-0.43 -1.07 -2.70 -2.00 -2.45 -2.46 -12.80 -1.42
Net Debt to EBITDA
0.21 3.99 1.29 2.79 1.48 0.97 0.32 -0.53
Long-Term Debt to EBITDA
-0.36 -1.07 -2.49 -1.95 -2.45 -2.46 -5.06 -1.40
Debt to NOPAT
-0.53 -1.26 -2.73 -1.84 -2.31 -2.57 -7.83 -1.36
Net Debt to NOPAT
0.26 4.69 1.30 2.58 1.40 1.01 0.20 -0.51
Long-Term Debt to NOPAT
-0.45 -1.26 -2.51 -1.80 -2.31 -2.57 -3.09 -1.35
Altman Z-Score
-3.79 5.43 2.20 2.83 -0.49 -0.93 -1.13 -3.65
Noncontrolling Interest Sharing Ratio
1,168.42% 173.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - -
Current Ratio
1.60 5.48 3.75 5.46 5.18 4.42 1.43 1.89
Quick Ratio
1.46 5.31 3.63 5.31 4.99 4.25 1.38 1.73
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -37 -234 -175 -123 -78 -127 -60
Operating Cash Flow to CapEx
-1,966.62% -1,647.93% -336.92% -221.74% -1,649.67% -2,745.23% 908.23% 79.11%
Free Cash Flow to Firm to Interest Expense
0.00 -7.21 -11.63 -10.61 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-19.91 -6.32 -1.30 -1.41 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-20.92 -6.71 -1.69 -2.04 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - -
Asset Turnover
1.01 0.75 0.43 0.34 0.35 0.41 0.39 0.46
Accounts Receivable Turnover
4.06 5.61 4.98 4.98 5.71 5.47 5.22 5.35
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
24.07 34.54 22.01 13.37 11.22 11.46 11.13 9.84
Accounts Payable Turnover
33.03 27.73 21.91 24.81 31.38 29.66 18.35 15.34
Days Sales Outstanding (DSO)
89.80 65.10 73.32 73.25 63.93 66.76 69.93 68.22
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
11.05 13.16 16.66 14.71 11.63 12.31 19.89 23.80
Cash Conversion Cycle (CCC)
78.75 51.93 56.66 58.53 52.30 54.46 50.03 44.42
Capital & Investment Metrics
- - - - - - - -
Invested Capital
24 22 189 263 288 277 356 303
Invested Capital Turnover
4.66 6.65 1.79 1.07 1.00 1.05 0.97 0.94
Increase / (Decrease) in Invested Capital
0.00 -1.73 166 74 25 -11 78 -52
Enterprise Value (EV)
581 1,089 1,763 1,803 445 443 421 227
Market Capitalization
182 1,269 1,850 2,062 582 533 430 169
Book Value per Share
($78.10) $5.49 $6.50 $10.03 $7.76 $6.38 $6.00 $3.47
Tangible Book Value per Share
($84.77) $4.69 $1.63 $4.75 $2.68 $1.79 $0.32 ($0.58)
Total Capital
57 249 460 708 652 595 748 399
Total Debt
22 48 183 186 227 228 382 153
Total Long-Term Debt
19 48 169 181 227 228 151 152
Net Debt
-11 -180 -87 -259 -137 -90 -9.64 58
Capital Expenditures (CapEx)
2.05 1.95 7.76 10 2.14 1.21 1.60 0.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-4.68 -12 -15 -25 -18 -13 -21 -14
Debt-free Net Working Capital (DFNWC)
29 216 256 420 345 304 371 81
Net Working Capital (NWC)
25 216 242 415 345 304 140 80
Net Nonoperating Expense (NNE)
20 22 48 53 39 29 21 65
Net Nonoperating Obligations (NNO)
-11 -178 -87 -259 -137 -90 -9.64 58
Total Depreciation and Amortization (D&A)
7.80 9.68 28 51 48 34 40 53
Debt-free, Cash-free Net Working Capital to Revenue
-4.16% -7.91% -7.77% -10.36% -6.59% -4.52% -6.86% -4.62%
Debt-free Net Working Capital to Revenue
25.33% 139.42% 135.66% 173.57% 125.00% 102.85% 121.01% 26.15%
Net Working Capital to Revenue
22.25% 139.42% 128.02% 171.68% 125.00% 102.85% 45.60% 25.63%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($2.91) ($3.23) ($2.56) ($2.09) ($1.15) ($2.55)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 44.04M 47.49M 53.72M 56.42M 60.18M 69.90M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($2.91) ($3.23) ($2.63) ($2.09) ($1.15) ($2.55)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 44.04M 47.49M 54.08M 56.42M 60.18M 69.90M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 ($2.91) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 39.54M 53.35M 55.81M 58.56M 70.21M 73.59M
Normalized Net Operating Profit after Tax (NOPAT)
-42 -38 -67 -101 -98 -89 -49 -35
Normalized NOPAT Margin
-37.37% -24.79% -35.63% -41.56% -35.48% -30.02% -15.94% -11.39%
Pre Tax Income Margin
-55.18% -38.69% -61.54% -66.18% -51.29% -39.80% -22.56% -56.97%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
-29.69 -10.78 -4.79 -8.73 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-20.78 -7.55 -3.35 -6.11 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-30.70 -11.16 -5.17 -9.36 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-21.80 -7.93 -3.74 -6.74 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-14.06% -7.67% 0.00% 0.00% -6.11% -1.53% 0.00% -2.81%

Quarterly Metrics And Ratios for Health Catalyst

This table displays calculated financial ratios and metrics derived from Health Catalyst's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - 70,210,651.00 69,601,233.00 70,373,625.00 70,730,884.00 73,586,183.00 73,894,020.00 75,256,381.00
DEI Adjusted Shares Outstanding
- - - - 70,210,651.00 69,601,233.00 70,373,625.00 70,730,884.00 73,586,183.00 73,894,020.00 75,256,381.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - -0.34 -0.59 -0.32 -1.29 -1.51 -0.55 0.54
Growth Metrics
- - - - - - - - - - -
Revenue Growth
1.16% 3.67% 3.50% 6.02% 6.28% 6.35% -0.04% -6.19% -10.90% -12.68% -26.26%
EBITDA Growth
45.64% 76.68% 81.37% 72.35% 45.53% -295.57% -41.04% -951.00% -1,143.30% -7.25% 2,942.80%
EBIT Growth
34.66% 54.34% 44.32% 46.62% 11.58% -134.67% -27.92% -391.89% -427.87% 1.66% 762.66%
NOPAT Growth
34.66% 54.34% 44.32% 46.62% 11.58% -134.67% -27.92% -391.89% -427.87% 1.66% 513.08%
Net Income Growth
37.97% 58.56% 33.16% 31.80% -15.33% -203.18% -50.95% -340.31% -367.64% 1.08% 282.18%
EPS Growth
41.67% 60.34% 38.46% 36.54% 0.00% -156.52% -33.33% -290.91% -337.14% 6.78% 265.63%
Operating Cash Flow Growth
283.98% 113.93% 99.29% 81.48% -97.27% -658.13% -107.47% 381.03% 6,511.07% 103.06% -304.09%
Free Cash Flow Firm Growth
-10.72% 4,884.64% -1,036.28% -646.75% -701.82% -278.53% -54.83% 91.18% 204.53% 156.57% 506.13%
Invested Capital Growth
1.16% -81.84% 19.23% 28.26% 50.09% 712.32% 25.80% -14.70% -56.26% -59.58% -83.08%
Revenue Q/Q Growth
-0.48% 1.58% 0.59% 4.26% -0.24% 1.65% -5.45% -2.15% -5.25% -0.38% -20.15%
EBITDA Q/Q Growth
44.52% 57.09% 47.32% -120.47% -9.30% -211.61% 81.22% -1,542.91% -29.30% 73.12% 597.87%
EBIT Q/Q Growth
30.42% 30.71% 13.41% -27.86% -15.26% -83.90% 52.80% -391.63% -23.70% 65.74% 418.05%
NOPAT Q/Q Growth
30.42% 30.71% 13.41% -27.86% -15.26% -83.90% 52.80% -391.63% -23.70% 65.74% 298.26%
Net Income Q/Q Growth
32.08% 34.35% -8.95% -40.38% -14.85% -72.60% 45.75% -309.49% -21.97% 63.49% 199.90%
EPS Q/Q Growth
32.69% 34.29% -4.35% -37.50% -6.06% -68.57% 45.76% -303.13% -18.60% 64.05% 196.36%
Operating Cash Flow Q/Q Growth
153.92% -84.30% 285.11% -156.81% 107.94% -3,313.21% 94.84% 2,236.21% 86.75% -98.51% -781.82%
Free Cash Flow Firm Q/Q Growth
-57.82% 1,210.44% -128.24% -50.88% -69.46% -147.24% 75.51% 91.41% 2,108.96% 33.79% 75.85%
Invested Capital Q/Q Growth
0.39% -82.16% 530.17% 13.67% 17.47% -3.46% -2.41% -22.93% -39.77% -10.78% -59.14%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
48.45% 47.22% 44.58% 43.58% 45.63% 47.37% 49.55% 52.74% 50.12% 49.46% 42.71%
EBITDA Margin
-18.57% -7.84% -4.11% -8.69% -9.52% -29.17% -5.80% -97.30% -132.79% -35.83% 223.40%
Operating Margin
-30.53% -20.83% -17.93% -21.98% -25.40% -45.95% -22.94% -115.27% -150.48% -51.75% 89.08%
EBIT Margin
-30.53% -20.83% -17.93% -21.98% -25.40% -45.95% -22.94% -115.27% -150.48% -51.75% 206.15%
Profit (Net Income) Margin
-27.55% -17.81% -19.29% -25.97% -29.90% -50.77% -29.12% -121.89% -156.91% -57.51% 71.95%
Tax Burden Percent
100.55% 100.52% 96.88% 103.12% 100.91% 100.20% 100.18% 100.42% 100.37% 100.78% 100.98%
Interest Burden Percent
89.75% 85.06% 111.06% 114.56% 116.64% 110.25% 126.72% 105.30% 103.88% 110.26% 34.56%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.98%
Return on Invested Capital (ROIC)
-22.92% -27.04% -13.18% -14.91% -15.90% -44.90% -14.37% -76.21% -106.14% -37.40% 106.43%
ROIC Less NNEP Spread (ROIC-NNEP)
-18.50% -25.88% -6.84% 2.05% 34.70% -32.97% -117.30% -204.73% -191.58% -62.85% 222.95%
Return on Net Nonoperating Assets (RNNOA)
5.07% 14.69% 1.50% -0.28% -1.80% 11.78% -3.31% -16.04% -31.78% -16.52% -8.12%
Return on Equity (ROE)
-17.85% -12.35% -11.68% -15.19% -17.70% -33.13% -17.68% -92.25% -137.92% -53.92% 98.31%
Cash Return on Invested Capital (CROIC)
-30.19% 96.91% -38.26% -40.20% -53.57% -183.50% -41.14% -18.31% 20.65% 23.90% 87.67%
Operating Return on Assets (OROA)
-12.52% -8.82% -7.10% -8.64% -9.97% -22.21% -10.36% -52.68% -69.83% -31.03% 136.11%
Return on Assets (ROA)
-11.30% -7.54% -7.64% -10.20% -11.73% -24.54% -13.15% -55.71% -72.81% -34.48% 47.51%
Return on Common Equity (ROCE)
-17.85% -12.35% -11.68% -15.19% -17.70% -33.13% -17.68% -92.25% -137.92% -53.92% 98.31%
Return on Equity Simple (ROE_SIMPLE)
-29.55% -24.21% -22.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-16 -11 -9.58 -12 -14 -26 -12 -60 -75 -26 51
NOPAT Margin
-21.37% -14.58% -12.55% -15.39% -17.78% -32.17% -16.06% -80.69% -105.34% -36.23% 89.95%
Net Nonoperating Expense Percent (NNEP)
-4.42% -1.16% -6.34% -16.96% -50.61% -11.93% 102.93% 128.53% 85.43% 25.46% -116.52%
Return On Investment Capital (ROIC_SIMPLE)
- - - -1.64% -1.86% -5.19% -2.53% -15.10% -25.57% -10.04% 34.78%
Cost of Revenue to Revenue
51.55% 52.78% 55.42% 56.42% 54.37% 52.63% 50.45% 47.26% 49.88% 50.54% 57.29%
SG&A Expenses to Revenue
19.49% 18.92% 15.99% 19.70% 17.83% 10.26% 21.05% 14.79% 19.73% 16.92% 21.32%
R&D to Revenue
19.90% 18.29% 18.59% 18.85% 19.12% 15.35% 16.09% 13.27% 13.82% 15.64% 16.88%
Operating Expenses to Revenue
78.98% 68.05% 62.51% 65.56% 71.03% 93.33% 72.49% 168.00% 200.60% 101.21% 70.70%
Earnings before Interest and Taxes (EBIT)
-23 -16 -14 -18 -20 -37 -18 -86 -106 -36 116
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-14 -5.95 -3.14 -6.91 -7.56 -24 -4.42 -73 -94 -25 126
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.21 1.06 1.39 1.18 0.84 0.76 0.60 0.69 0.68 1.46 0.89
Price to Tangible Book Value (P/TBV)
4.32 4.49 11.14 22.18 0.00 0.00 0.00 0.00 0.00 4.38 1.54
Price to Revenue (P/Rev)
1.46 1.26 1.63 1.40 1.02 0.83 0.63 0.54 0.31 0.50 0.48
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.27 1.41 1.44 1.18 0.86 0.79 0.67 0.75 0.76 1.21 0.77
Enterprise Value to Revenue (EV/Rev)
1.19 0.23 1.49 1.37 1.15 1.01 0.83 0.73 0.46 0.67 0.19
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 28.89 78.49 0.00 0.00 309.94 7.28 6.98 1.91
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.45 0.00 0.00 0.00 0.00 0.00 0.00 2.23 2.91 0.25
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.70 0.00 0.97 1.05 1.02 0.44 0.46 0.62 1.11 1.52 0.00
Long-Term Debt to Equity
0.69 0.00 0.32 0.41 0.40 0.44 0.46 0.62 1.10 1.51 0.00
Financial Leverage
-0.27 -0.57 -0.22 -0.14 -0.05 -0.36 0.03 0.08 0.17 0.26 -0.04
Leverage Ratio
1.90 1.89 2.07 2.13 2.16 1.86 2.04 2.23 2.53 2.17 1.73
Compound Leverage Factor
1.70 1.61 2.30 2.44 2.52 2.05 2.58 2.35 2.63 2.40 0.60
Debt to Total Capital
41.06% 0.25% 49.29% 51.15% 50.40% 30.57% 31.57% 38.41% 52.61% 60.35% 0.00%
Short-Term Debt to Total Capital
0.55% 0.25% 32.91% 30.92% 30.48% 0.33% 0.34% 0.41% 0.56% 0.64% 0.00%
Long-Term Debt to Total Capital
40.51% 0.00% 16.37% 20.22% 19.92% 30.25% 31.24% 38.00% 52.05% 59.71% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
58.94% 99.75% 50.71% 48.85% 49.60% 69.43% 68.43% 61.59% 47.39% 39.65% 100.00%
Debt to EBITDA
-3.06 -0.01 -7.19 -12.80 -16.25 -3.72 -3.61 -1.42 -0.79 -0.78 0.00
Net Debt to EBITDA
0.97 4.98 0.88 0.32 -1.74 -1.35 -1.45 -0.53 -0.23 -0.25 0.00
Long-Term Debt to EBITDA
-3.02 0.00 -2.39 -5.06 -6.42 -3.68 -3.57 -1.40 -0.78 -0.77 0.00
Debt to NOPAT
-3.10 -0.01 -5.79 -7.83 -8.14 -2.47 -2.37 -1.36 -0.89 -0.89 0.00
Net Debt to NOPAT
0.98 4.57 0.71 0.20 -0.87 -0.90 -0.95 -0.51 -0.26 -0.29 0.00
Long-Term Debt to NOPAT
-3.06 0.00 -1.92 -3.09 -3.22 -2.45 -2.35 -1.35 -0.88 -0.88 0.00
Altman Z-Score
-0.68 -1.20 -0.85 -0.93 -1.14 -1.78 -1.97 -3.16 -4.71 -4.57 -4.82
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.31 1.18 1.41 1.43 1.24 1.83 1.88 1.89 1.69 2.70 1.70
Quick Ratio
4.14 1.14 1.36 1.38 1.20 1.68 1.73 1.73 1.56 1.58 1.54
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-19 213 -60 -91 -154 -380 -93 -7.99 160 215 378
Operating Cash Flow to CapEx
5,007.80% 563.64% 884.33% -860.24% 42.23% 0.00% -186.35% 3,812.31% 5,542.22% 82.34% -1,293.10%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 39.77
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.20
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.41 0.42 0.40 0.39 0.39 0.48 0.45 0.46 0.46 0.60 0.66
Accounts Receivable Turnover
5.13 5.58 6.18 5.22 5.28 5.13 5.66 5.35 4.91 5.30 5.37
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
11.61 11.59 11.19 11.13 11.05 10.72 10.45 9.84 9.09 8.74 8.12
Accounts Payable Turnover
22.00 17.76 16.06 18.35 23.28 17.70 17.59 15.34 14.69 16.75 24.13
Days Sales Outstanding (DSO)
71.17 65.37 59.05 69.93 69.14 71.17 64.53 68.22 74.33 68.87 68.01
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
16.59 20.55 22.73 19.89 15.68 20.63 20.75 23.80 24.85 21.79 15.12
Cash Conversion Cycle (CCC)
54.57 44.82 36.32 50.03 53.46 50.55 43.78 44.42 49.48 47.08 52.89
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
278 50 313 356 418 403 394 303 183 163 67
Invested Capital Turnover
1.07 1.85 1.05 0.97 0.89 1.40 0.89 0.94 1.01 1.03 1.18
Increase / (Decrease) in Invested Capital
3.18 -224 50 78 139 354 81 -52 -235 -240 -327
Enterprise Value (EV)
354 70 450 421 359 318 262 227 138 197 51
Market Capitalization
433 377 492 430 318 262 201 169 93 147 130
Book Value per Share
$6.10 $6.05 $5.87 $6.00 $5.37 $4.99 $4.72 $3.47 $1.88 $1.36 $1.93
Tangible Book Value per Share
$1.71 $1.42 $0.73 $0.32 ($0.61) ($0.53) ($0.61) ($0.58) ($0.60) $0.45 $1.12
Total Capital
606 358 700 748 760 501 485 399 292 254 146
Total Debt
249 0.89 345 382 383 153 153 153 153 153 0.00
Total Long-Term Debt
246 0.00 115 151 151 151 152 152 152 152 0.00
Net Debt
-79 -307 -42 -9.64 41 56 62 58 45 50 -79
Capital Expenditures (CapEx)
0.21 0.29 0.70 0.41 0.66 -0.25 0.25 0.26 0.33 0.33 0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-20 -249 -23 -21 -27 -14 -12 -14 -32 55 -24
Debt-free Net Working Capital (DFNWC)
308 59 364 371 315 83 79 81 76 158 55
Net Working Capital (NWC)
305 58 134 140 83 82 77 80 75 156 55
Net Nonoperating Expense (NNE)
4.62 2.45 5.15 8.42 9.62 15 9.97 31 36 15 10
Net Nonoperating Obligations (NNO)
-79 -307 -42 -9.64 41 56 62 58 45 62 -79
Total Depreciation and Amortization (D&A)
8.94 9.85 11 11 13 14 13 13 13 11 9.71
Debt-free, Cash-free Net Working Capital to Revenue
-6.57% -83.25% -7.68% -6.86% -8.75% -4.42% -3.94% -4.62% -10.74% 18.70% -8.88%
Debt-free Net Working Capital to Revenue
103.87% 19.68% 120.52% 121.01% 101.11% 26.38% 25.02% 26.15% 25.23% 54.10% 20.14%
Net Working Capital to Revenue
102.74% 19.38% 44.24% 45.60% 26.71% 25.86% 24.51% 25.63% 24.70% 53.54% 20.14%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.35) ($0.23) ($0.24) ($0.33) ($0.35) ($0.59) ($0.32) ($1.29) ($1.53) ($0.55) $0.54
Adjusted Weighted Average Basic Shares Outstanding
58.59M 59.30M 60.44M 60.18M 68.55M 69.63M 70.38M 69.90M 72.59M 73.96M 75.39M
Adjusted Diluted Earnings per Share
($0.35) ($0.23) ($0.24) ($0.33) ($0.35) ($0.59) ($0.32) ($1.29) ($1.53) ($0.55) $0.53
Adjusted Weighted Average Diluted Shares Outstanding
58.59M 59.30M 60.44M 60.18M 68.55M 69.63M 70.38M 69.90M 72.59M 73.96M 75.93M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
59.03M 60.47M 60.85M 70.21M 69.60M 70.37M 70.73M 73.59M 73.89M 75.26M 76.16M
Normalized Net Operating Profit after Tax (NOPAT)
-16 -11 -9.58 -12 -14 -5.83 -12 -60 -7.68 -6.60 35
Normalized NOPAT Margin
-21.37% -14.58% -12.55% -15.39% -17.78% -7.22% -16.06% -80.69% -10.86% -9.37% 62.36%
Pre Tax Income Margin
-27.40% -17.71% -19.91% -25.18% -29.63% -50.66% -29.07% -121.38% -156.33% -57.06% 71.25%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.22
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.33
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.21
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.32
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% -6.88% -4.99% -4.65% -2.81% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Health Catalyst’s latest financial statements show improving cash flow and gross margins, but the company remains unprofitable and has experienced a significant deterioration in its asset base. In Q2 2026, revenue was $70.5 million, down slightly from $70.8 million in Q1 2026 and down 12.6% from $80.7 million in Q2 2025. Revenue has remained broadly stable compared with the $68.4 million reported in Q3 2022, but the company has not established a clear growth trend.

Gross profit was $34.9 million in Q2 2026, representing a 49.5% gross margin. That margin improved from 47.4% in Q2 2025 and 46.7% in Q1 2026, suggesting better cost control at the delivery level. However, operating expenses totaled $71.3 million, more than twice gross profit. Health Catalyst reported a $40.5 million net loss, or $0.55 per share, although that was an improvement from the $111.0 million loss in Q1 2026. The Q1 and Q2 results were heavily affected by impairment charges of $95.5 million and $27.0 million, respectively.

Liquidity has improved modestly in the near term, but the longer-term balance-sheet trend is unfavorable. Cash and short-term investments totaled $103.4 million at June 30, 2026, compared with $348.3 million at March 31, 2024. Total debt was approximately $153.5 million, while shareholders’ equity fell to $100.8 million from $347.5 million in Q2 2025. Operating cash flow was slightly positive at $275,000 in Q2 2026, following $18.5 million in Q1, but continued losses and recurring noncash adjustments make the durability of cash generation an important issue for investors.

  • Gross margin improved: Q2 2026 gross margin increased to approximately 49.5%, compared with 47.4% in Q2 2025 and 45.3% in Q3 2022.
  • Operating cash flow turned positive: Health Catalyst generated $275,000 of operating cash flow in Q2 2026 after generating $18.5 million in Q1 2026, compared with an operating cash outflow of $9.0 million in Q2 2025.
  • Quarterly net loss narrowed sequentially: The Q2 2026 net loss of $40.5 million was substantially lower than the $111.0 million loss in Q1 2026, primarily because impairment charges declined.
  • Current liquidity remains adequate: Q2 2026 current assets of $248.4 million exceeded current liabilities of $91.9 million, providing a current ratio of roughly 2.7.
  • Revenue is relatively stable but not growing: Quarterly revenue has generally remained in the $68 million to $81 million range since Q3 2022, with Q2 2026 revenue down from the 2025 peak.
  • Investment balances provide financial flexibility: Cash and short-term investments totaled $103.4 million at the end of Q2 2026, but much of the company’s historical liquidity has been consumed since early 2024.
  • Persistent GAAP losses: Health Catalyst has reported a net loss in each quarterly income statement provided, including a $40.5 million loss in Q2 2026.
  • Large impairment charges raise asset-quality concerns: The company recorded $95.5 million of impairment expense in Q1 2026 and another $27.0 million in Q2. Goodwill declined from $286.1 million in Q2 2025 to $11.1 million in Q2 2026, indicating substantial write-downs.
  • Revenue declined year over year: Q2 2026 revenue fell 12.6% from Q2 2025, while selling, general and administrative, marketing, research and development, and depreciation expenses continued to consume most of gross profit.
  • Balance-sheet strength has weakened: Total assets declined to $358.6 million from $616.2 million in Q2 2025, equity fell to $100.8 million, and total debt remained elevated at approximately $153.5 million.
11/19/26 02:48 AM ETAI Generated. May Contain Errors.

Health Catalyst Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Health Catalyst's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Health Catalyst's net income appears to be on a downward trend, with a most recent value of -$177.97 million in 2025, falling from -$61.98 million in 2018. The previous period was -$69.50 million in 2024. View Health Catalyst's forecast to see where analysts expect Health Catalyst to go next.

Health Catalyst's total operating income in 2025 was -$160.85 million, based on the following breakdown:
  • Total Gross Profit: $151.68 million
  • Total Operating Expenses: $312.53 million

Over the last 7 years, Health Catalyst's total revenue changed from $112.57 million in 2018 to $311.14 million in 2025, a change of 176.4%.

In the past 13 quarters, Health Catalyst's cash and equivalents has ranged from $40.31 million in Q3 2025 to $341.97 million in Q1 2025, and is currently $53.75 million as of their latest financial filing in Q3 2026.

Health Catalyst had total debt of $153.25 million at the end of 2025, a 59.9% decrease from 2024, and a 588.1% increase since 2018.

Over the last 7 years, Health Catalyst's book value per share changed from -78.10 in 2018 to 3.47 in 2025.



Financial statements for NASDAQ:HCAT last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners